Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Sales (2022 - 2025)

Taysha Gene Therapies' Return on Sales history spans 4 years, with the latest figure at 14.92% for Q3 2025.

  • For Q3 2025, Return on Sales fell 160.0% year-over-year to 14.92%; the TTM value through Sep 2025 reached 14.92%, down 671.0%, while the annual FY2024 figure was 10.15%, 537.0% down from the prior year.
  • Return on Sales for Q3 2025 was 14.92% at Taysha Gene Therapies, down from 12.54% in the prior quarter.
  • Across five years, Return on Sales topped out at 74.86% in Q1 2022 and bottomed at 17.88% in Q2 2024.
  • The 4-year median for Return on Sales is 6.64% (2024), against an average of 4.59%.
  • The largest annual shift saw Return on Sales tumbled -7861bps in 2023 before it skyrocketed 534bps in 2025.
  • A 4-year view of Return on Sales shows it stood at 42.2% in 2022, then plummeted by -110bps to 4.17% in 2023, then crashed by -116bps to 9.03% in 2024, then crashed by -65bps to 14.92% in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Return on Sales are 14.92% (Q3 2025), 12.54% (Q2 2025), and 8.74% (Q1 2025).